Suppr超能文献

[抗CD105和抗CD34检测肝细胞癌患者肿瘤微血管密度及其对肝移植后肿瘤复发的预测价值]

[Tumor microvascular density detected by anti-CD105 and anti-CD34 in hepatocellular carcinoma patients and its predictive value of tumor recurrence after liver transplantation].

作者信息

Wang Yu, Zhang Xiu-hui, Guo Peng, Yan Lü-nan, He Du

机构信息

Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.

出版信息

Sichuan Da Xue Xue Bao Yi Xue Ban. 2010 Sep;41(5):818-21.

Abstract

OBJECTIVE

To investigate the clinical significance of tumor microvascular density (MVD) detected by anti-CD105 and anti-CD34 as a predictor of recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT).

METHODS

One hundred and twelve (100 with adjacent nontumorous area) patients with HCC who underwent LT between Jan. 2001 and Dec. 2006 were included in this retrospective study. Paraffin blocks of tumor tissue and adjacent nontumorous tissue were used for immunohistochemical study. MVD of HCC was evaluated by anti-CD105 monoclonal antibody and anti-CD34 monoclonal antibody.

RESULTS

The immunohistochemich staining showed CD34 strongly positive expressed in the tumor area with tumor mature vasculature, and CD105 strongly positive expressed in adjacent nontumorous area with tumor newly formed vessels. Univariate analysis using chi-square test showed portal vein tumor thrombus (PVTT), pTNM stage, MVD-CD105 expression in adjacent nontumorous area, tumor size and serum AFP level were significantly associated with HCC recurrence after LT (P < 0.05). Multivariate analysis by Cox's regression model showed MVD-CD105 expression in adjacent nontumorous area and PVTT still remained significant correlation with recurrence of HCC after LT (P < 0.05), and MVD-CD105 in adjacent nontumorous area was significantly correlated with PVTT (r(s) = 0.257, P = 0.01), pTNM stage (r(s) = 0.350, P = 0.000), as well as serum AFP level (r(s) = 0.208, P = 0.038).

CONCLUSION

The anti-CD105 mAb is an ideal tool to quantify new microvessels in HCC. MVD-CD105 expression in adjacent nontumorous area may be used as an additional factor for the identification of patients at risk for post-transplant recurrence.

摘要

目的

探讨抗CD105和抗CD34检测的肿瘤微血管密度(MVD)作为肝移植(LT)后肝细胞癌(HCC)复发预测指标的临床意义。

方法

本回顾性研究纳入了2001年1月至2006年12月期间接受LT的112例HCC患者(其中100例伴有癌旁非肿瘤组织)。肿瘤组织和癌旁非肿瘤组织的石蜡块用于免疫组织化学研究。采用抗CD105单克隆抗体和抗CD34单克隆抗体评估HCC的MVD。

结果

免疫组织化学染色显示,CD34在具有成熟肿瘤血管的肿瘤区域呈强阳性表达,而CD105在具有肿瘤新生血管的癌旁非肿瘤区域呈强阳性表达。采用卡方检验的单因素分析显示,门静脉癌栓(PVTT)、pTNM分期、癌旁非肿瘤区域的MVD-CD105表达、肿瘤大小和血清AFP水平与LT后HCC复发显著相关(P < 0.05)。采用Cox回归模型的多因素分析显示,癌旁非肿瘤区域的MVD-CD105表达和PVTT与LT后HCC复发仍具有显著相关性(P < 0.05),且癌旁非肿瘤区域的MVD-CD105与PVTT(r(s) = 0.257,P = 0.01)、pTNM分期(r(s) = 0.350,P = 0.000)以及血清AFP水平(r(s) = 0.208,P = 0.038)显著相关。

结论

抗CD105单克隆抗体是定量HCC中新微血管的理想工具。癌旁非肿瘤区域的MVD-CD105表达可作为识别移植后复发高危患者的一个附加因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验